CDE: it is planned to include the Amgen bispecific antibody blincyto in the priority review

Yesterday, according to the new drug development monitoring database (CPM), CDE plans to include the anti Amgen bispecific antibody blincyto (Bluetooth / bilintomomab) in the priority review ▲ spatial conformation of bluemomab Bilintomolobib is a kind of bite molecule developed by Amgen based on its bite platform, which targets CD19 and CD3 at the same time It is also the first FDA approved bispecific antibody of the company's bite technology platform One end can bind to CD19 antigen on the surface of B cells, while the other end can bind to CD3 receptor on the surface of effector T cells Therefore, the drug can collect T cells to the vicinity of cancer cells and promote their killing to cancer cells Data source: drug sharing plus So far, three bispecific antibodies have been approved in the world In view of the delisting of removab, which was first approved for listing, in 2017, only Amgen's blincyto and Roche's hemlibra (emcezumab) are sold on the market The latter is similar to coagulation factor VIII According to PDB, blincyto has performed well in the global market, reaching US $210 million in 2018, which is in line with the growth rate of over 45% Data source: PDB drug comprehensive database According to the new drug development monitoring database (CPM), belindormib has been accepted by CDE on October 25, 2019, and its indication is relapsed / refractory (R / R) precursor B-cell acute lymphoblastic leukemia, which is consistent with the indication approved by FDA.